See more : Huadian Heavy Industries Co., Ltd. (601226.SS) Income Statement Analysis – Financial Results
Complete financial analysis of DDS,Inc. (3782.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DDS,Inc., a leading company in the Security & Protection Services industry within the Industrials sector.
You may be interested
- Pacific Edge Limited (PFGTF) Income Statement Analysis – Financial Results
- Immobiliare Grande Distribuzione SIIQ S.p.A. (IMMQF) Income Statement Analysis – Financial Results
- Portofino Resources Inc. (PFFOF) Income Statement Analysis – Financial Results
- Shanghai Pudong Construction Co.,Ltd. (600284.SS) Income Statement Analysis – Financial Results
- Glenfarne Merger Corp. (GGMCU) Income Statement Analysis – Financial Results
DDS,Inc. (3782.T)
About DDS,Inc.
DDS,Inc. engages in the biometrics business in Japan. It is involved in the research, development, and sale of information technology-related products, such as fingerprint authentication systems for PCs and cell phones using biometric authentication technology. The company offers UBF fingerprint authentication products for PCs, laptops, and tablet PCs. It also provides EVE MA, a multifactor authentication platform; EVE FA, a two-factor authentication platform; Themis, a universal authentication platform; Magatama Platform, a cloud identity authentication solution; Dokodemo Personal Identification, a solution for online face-to-face personal identification; and hybrid fingerprint authentication system development kit, as well as Magatama Service, a cloud identity authentication service. In addition, the company offers customized development system covering a range of technologies and product fields. DDS,Inc. was founded in 1992 and is headquartered in Nagoya, Japan.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 942.78M | 1.18B | 1.16B | 1.16B | 1.22B | 790.43M | 1.20B | 605.66M | 611.62M | 530.00M | 628.37M | 519.07M | 457.80M | 370.02M | 1.89B |
| Cost of Revenue | 445.68M | 626.99M | 586.57M | 469.67M | 426.34M | 304.95M | 369.96M | 248.59M | 211.79M | 225.88M | 188.05M | 185.92M | 187.19M | 270.92M | 1.30B |
| Gross Profit | 497.10M | 550.72M | 569.85M | 694.35M | 788.80M | 485.48M | 826.86M | 357.07M | 399.83M | 304.12M | 440.32M | 333.15M | 270.61M | 99.10M | 594.54M |
| Gross Profit Ratio | 52.73% | 46.76% | 49.28% | 59.65% | 64.91% | 61.42% | 69.09% | 58.96% | 65.37% | 57.38% | 70.07% | 64.18% | 59.11% | 26.78% | 31.41% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 701.50M | 823.74M | 723.64M | 859.23M | 23.11M | -7.51M | 45.83M | 67.09M | 60.62M | -35.79M | 5.52M | -1.87M | 15.81M | -12.69M | 966.00K |
| Operating Expenses | 701.50M | 823.74M | 723.64M | 859.23M | 727.25M | 719.33M | 767.27M | 917.40M | 738.96M | 549.97M | 405.26M | 393.01M | 377.87M | 521.47M | 824.33M |
| Cost & Expenses | 1.15B | 1.45B | 1.31B | 1.33B | 1.15B | 1.02B | 1.14B | 1.17B | 950.75M | 775.84M | 593.30M | 578.93M | 565.07M | 792.39M | 2.12B |
| Interest Income | 32.00K | 2.00M | 4.00M | 3.61M | 161.00K | 375.00K | 261.00K | 1.01M | 2.05M | 805.00K | 232.00K | 1.15M | 1.17M | 1.23M | 1.18M |
| Interest Expense | 1.06B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 920.00K | 367.00K | 4.50M | 32.79M | 27.02M | 20.49M | 27.16M | 40.40M | 18.43M |
| Depreciation & Amortization | 14.34M | 46.20M | 19.04M | -216.25M | 35.08M | 27.17M | 67.39M | 87.92M | 68.80M | 91.97M | 78.23M | 127.66M | 114.88M | 141.14M | 163.18M |
| EBITDA | 260.35M | 252.70M | -134.75M | -381.12M | 1.07B | -206.68M | 150.12M | -424.87M | -119.09M | -134.73M | 163.94M | 57.83M | -17.47M | -267.98M | -185.73M |
| EBITDA Ratio | 27.62% | 21.46% | -11.65% | -32.74% | 88.08% | -26.15% | 12.54% | -70.15% | -19.47% | -25.42% | 26.09% | 11.14% | -3.82% | -72.42% | -9.81% |
| Operating Income | 246.02M | 206.51M | -153.79M | -164.88M | 61.56M | -233.85M | 59.59M | -560.33M | -339.13M | -245.84M | 35.07M | -59.86M | -107.27M | -422.37M | -229.79M |
| Operating Income Ratio | 26.09% | 17.53% | -13.30% | -14.16% | 5.07% | -29.59% | 4.98% | -92.52% | -55.45% | -46.39% | 5.58% | -11.53% | -23.43% | -114.15% | -12.14% |
| Total Other Income/Expenses | -1.06B | -946.23M | -15.72M | 202.16M | -978.95M | 30.38M | 31.92M | 12.67M | 240.58M | -49.19M | -76.78M | 52.33M | -145.76M | -978.07M | -1.46B |
| Income Before Tax | -815.76M | -739.73M | -169.51M | 37.28M | -917.39M | -203.47M | 91.51M | -547.66M | -98.54M | -295.03M | -41.72M | -7.53M | -253.03M | -1.40B | -1.69B |
| Income Before Tax Ratio | -86.53% | -62.81% | -14.66% | 3.20% | -75.50% | -25.74% | 7.65% | -90.42% | -16.11% | -55.67% | -6.64% | -1.45% | -55.27% | -378.48% | -89.36% |
| Income Tax Expense | 1.93M | -42.66M | 3.99M | 14.10M | -7.57M | 12.42M | 17.50M | 2.44M | 2.44M | 1.91M | 1.66M | 918.00K | 2.34M | 9.81M | 137.04M |
| Net Income | -817.69M | -697.06M | -173.49M | 23.18M | -909.82M | -215.89M | 74.02M | -550.10M | -100.98M | -296.93M | -43.38M | -8.45M | -255.37M | -1.41B | -1.83B |
| Net Income Ratio | -86.73% | -59.19% | -15.00% | 1.99% | -74.87% | -27.31% | 6.18% | -90.83% | -16.51% | -56.03% | -6.90% | -1.63% | -55.78% | -381.13% | -96.60% |
| EPS | -16.93 | -14.45 | -3.92 | 0.56 | -22.60 | -5.69 | 2.02 | -15.70 | -3.04 | -9.44 | -1.60 | -0.33 | -20.94 | -196.90 | -398.63 |
| EPS Diluted | -16.93 | -14.45 | -3.92 | 0.56 | -22.60 | -5.69 | 1.90 | -15.70 | -3.04 | -9.44 | -1.60 | -0.33 | -20.94 | -196.90 | -398.63 |
| Weighted Avg Shares Out | 48.29M | 48.24M | 44.26M | 41.60M | 40.26M | 37.96M | 36.56M | 35.03M | 33.25M | 31.45M | 27.13M | 25.97M | 12.20M | 7.16M | 4.59M |
| Weighted Avg Shares Out (Dil) | 48.29M | 48.24M | 44.26M | 41.60M | 40.26M | 37.96M | 38.96M | 35.03M | 33.25M | 31.45M | 27.13M | 25.97M | 12.20M | 7.16M | 4.59M |
Baxter Broadens Efforts to Increase Awareness, Education and Support of Kidney Health in Black Communities
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, announces the national expansion of its partnership with international not-for-profit organization The Links, Incorporated (The Links) to continue bringing awareness and resources for the disproportionate challenges affecting Black Americans related...
TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial, Studying the Delivery of SD-101 via Pressure-Enabled Drug Delivery in Adults with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
DENVER & CHICAGO--(BUSINESS WIRE)--TriSalus Life Sciences®, an immunotherapy company on a mission to extend and improve the lives of patients living with liver and pancreatic tumors, today announced the enrollment of the first patient in its Pressure-Enabled Regional Immuno-Oncology (PERIO™-02)...
Family Dollar Stores Issues Voluntary Recall of Certain FDA-Regulated Products in Six States Including Drugs, Devices, Cosmetics, Foods
CHESAPEAKE, Va.--(BUSINESS WIRE)--Family Dollar, Inc. is initiating a voluntary retail level product recall of certain products regulated by the U.S. Food and Drug Administration (FDA) that were stored and shipped to 404 stores from Family Dollar Distribution Center 202 in...
Form 8.3 - SIBANYE GOLD LIMITED
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION The naming of nominee or vehicle companies is...
Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for EXONDYS 51™ (eteplirsen) as a once weekly intravenous infusion of 30 milligrams per...
Form 8.3 - Liberty Global Plc
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION The naming of nominee or vehicle companies is...
Research and Markets: Brazil's Mining Fiscal Regime: H2 2014 - Coal, Iron Ore, Copper, Zinc, Bauxite, Gold, Chromium, Nickel, Platinum, Diamond, Uranium and Manganese
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/r5t8vf/brazils_mining) has announced the addition of the "Brazil's Mining Fiscal Regime: H2 2014" report to their offering. Brazilian fiscal regime report covers the governing bodies, governing laws, licenses, rights and obligations and tax-related information on 12...
Source: https://incomestatements.info
Category: Stock Reports